Literature DB >> 27338862

Antithrombotic Selection in ST-Segment Elevation Myocardial Infarction: a Year in Review.

Jad Raffoul1, Ammar Nasir1, Andrew J P Klein2,3.   

Abstract

OPINION STATEMENT: In ST-segment elevation myocardial infarction (STEMI), interventional cardiologists must move quickly to safely re-establish blood flow while choosing an antithrombotic to preclude wire thrombosis, aid in the restoration of flow, minimize thrombus propagation, and reduce the risk of stent thrombosis. Currently, operators have a choice between heparin and bivalirudin with the possible addition of glycoprotein IIb/IIIa inhibitors (GPIs). Prior studies have shown that bivalirudin use lowers rates of bleeding, but with a clear risk of acute stent thrombosis. Recent studies have examined this question in the modern era of radial access and newer antiplatelet agents. Despite these studies, there remains a question regarding which antithrombotic agent is to be selected in STEMI.

Entities:  

Keywords:  Acute stent thrombosis; Coronary artery disease; STEMI; Treatment

Year:  2016        PMID： 27338862     DOI： 10.1007/s11936-016-0473-7

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN： 1092-8464


  16 in total

1.  Choice of optimal anticoagulant to support primary PCI: out with the new, in with the old.

Authors:  Sanjay Kaul
Journal:  J Am Coll Cardiol       Date:  2015-01-06       Impact factor: 24.094

2.  Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary PCI: An updated meta-analysis of 10,350 patients from five randomized clinical trials.

Authors:  Davide Capodanno; Giuseppe Gargiulo; Piera Capranzano; Roxana Mehran; Corrado Tamburino; Gregg W Stone
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2015-03-06

3.  Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial.

Authors:  Gregg W Stone; Bernhard Witzenbichler; Giulio Guagliumi; Jan Z Peruga; Bruce R Brodie; Dariusz Dudek; Ran Kornowski; Franz Hartmann; Bernard J Gersh; Stuart J Pocock; George Dangas; S Chiu Wong; Martin Fahy; Helen Parise; Roxana Mehran
Journal:  Lancet       Date:  2011-06-12       Impact factor: 79.321

4.  Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site andSystemic Implementation of AngioX (MATRIX) trial.

Authors:  Marco Valgimigli; Paolo Calabrò; Bernardo Cortese; Enrico Frigoli; Stefano Garducci; Paolo Rubartelli; Giuseppe Andò; Andrea Santarelli; Mario Galli; Roberto Garbo; Alessandra Repetto; Salvatore Ierna; Carlo Briguori; Ugo Limbruno; Roberto Violini; Andrea Gagnor
Journal:  J Cardiovasc Transl Res       Date:  2014-01-07       Impact factor: 4.132

5.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

Authors:  A Michael Lincoff; John A Bittl; Robert A Harrington; Frederick Feit; Neal S Kleiman; J Daniel Jackman; Ian J Sarembock; David J Cohen; Douglas Spriggs; Ramin Ebrahimi; Gadi Keren; Jeffrey Carr; Eric A Cohen; Amadeo Betriu; Walter Desmet; Dean J Kereiakes; Wolfgang Rutsch; Robert G Wilcox; Pim J de Feyter; Alec Vahanian; Eric J Topol
Journal:  JAMA       Date:  2003-02-19       Impact factor: 56.272

6.  Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials.

Authors:  Gregg W Stone; Roxana Mehran; Patrick Goldstein; Bernhard Witzenbichler; Arnoud Van't Hof; Giulio Guagliumi; Christian W Hamm; Philippe Généreux; Peter Clemmensen; Stuart J Pocock; Bernard J Gersh; Debra Bernstein; Efthymios N Deliargyris; Philippe Gabriel Steg
Journal:  J Am Coll Cardiol       Date:  2015-01-06       Impact factor: 24.094

7.  Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.

Authors:  Yaling Han; Jincheng Guo; Yang Zheng; Hongyun Zang; Xi Su; Yu Wang; Shaoliang Chen; Tiemin Jiang; Ping Yang; Jiyan Chen; Dongju Jiang; Quanmin Jing; Zhenyang Liang; Haiwei Liu; Xin Zhao; Jing Li; Yi Li; Bo Xu; Gregg W Stone
Journal:  JAMA       Date:  2015-04-07       Impact factor: 56.272

8.  Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial.

Authors:  Adeel Shahzad; Ian Kemp; Christine Mars; Keith Wilson; Claire Roome; Rob Cooper; Mohammed Andron; Clare Appleby; Mike Fisher; Aleem Khand; Babu Kunadian; Joseph D Mills; John L Morris; William L Morrison; Shahzad Munir; Nick D Palmer; Raphael A Perry; David R Ramsdale; Periaswamy Velavan; Rod H Stables
Journal:  Lancet       Date:  2014-07-04       Impact factor: 79.321

9.  Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials.

Authors:  Salvatore Cassese; Robert A Byrne; Karl-Ludwig Laugwitz; Heribert Schunkert; Peter B Berger; Adnan Kastrati
Journal:  EuroIntervention       Date:  2015-06       Impact factor: 6.534

10.  Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials.

Authors:  Anthony A Bavry; Islam Y Elgendy; Ahmed Mahmoud; Manoj P Jadhav; Tianyao Huo
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.